Psychostimulant drugs for cocaine dependence.
BACKGROUND
Cocaine dependence is a severe disorder for which no medication has been approved. Like opioids for heroin dependence, replacement therapy with psychostimulants could be an effective therapy for treatment.


OBJECTIVE
To assess the effects of psychostimulants for cocaine abuse and dependence. Specific outcomes include sustained cocaine abstinence and retention in treatment. We also studied the influence of type of drug and comorbid disorders on psychostimulant efficacy.


METHODS
This is an update of the review previously published in 2010. For this updated review, we searched the Cochrane Drugs and Alcohol Group Trials Register, CENTRAL, MEDLINE, Embase and PsycINFO up to 15 February 2016. We handsearched references of obtained articles and consulted experts in the field.


METHODS
We included randomised parallel group controlled clinical trials comparing the efficacy of a psychostimulant drug versus placebo.


METHODS
We used standard methodological procedures expected by Cochrane.


RESULTS
We included 26 studies involving 2366 participants. The included studies assessed nine drugs: bupropion, dexamphetamine, lisdexamfetamine, methylphenidate, modafinil, mazindol, methamphetamine, mixed amphetamine salts and selegiline. We did not consider any study to be at low risk of bias for all domains included in the Cochrane 'Risk of bias' tool. Attrition bias was the most frequently suspected potential source of bias of the included studies. We found very low quality evidence that psychostimulants improved sustained cocaine abstinence (risk ratio (RR) 1.36, 95% confidence interval (CI) 1.05 to 1.77, P = 0.02), but they did not reduce cocaine use (standardised mean difference (SMD) 0.16, 95% CI -0.02 to 0.33) among participants who continued to use it. Furthermore, we found moderate quality evidence that psychostimulants did not improve retention in treatment (RR 1.00, 95% CI 0.93 to 1.06). The proportion of adverse event-induced dropouts and cardiovascular adverse event-induced dropouts was similar for psychostimulants and placebo (RD 0.00, 95% CI -0.01 to 0.01; RD 0.00, 95% CI -0.02 to 0.01, respectively). When we included the type of drug as a moderating variable, the proportion of patients achieving sustained cocaine abstinence was higher with bupropion and dexamphetamine than with placebo. Psychostimulants also appeared to increase the proportion of patients achieving sustained cocaine and heroin abstinence amongst methadone-maintained, dual heroin-cocaine addicts. Retention to treatment was low, though, so our results may be compromised by attrition bias. We found no evidence of publication bias.


CONCLUSIONS
This review found mixed results. Psychostimulants improved cocaine abstinence compared to placebo in some analyses but did not improve treatment retention. Since treatment dropout was high, we cannot rule out the possibility that these results were influenced by attrition bias. Existing evidence does not clearly demonstrate the efficacy of any pharmacological treatment for cocaine dependence, but substitution treatment with psychostimulants appears promising and deserves further investigation.
Unit of Clinical Pharmacology, TransLab Research Group, Department of Medical Sciences, Universitat de Girona, Emili Grahit, 77, Girona, Catalonia, Spain, 17071.
Xavier
X
Castells
Ruth
R
Cunill
Clara
C
Pérez-Mañá
Xavier
X
Vidal
Dolors
D
Capellà
Addiction. 2014 Sep;109(9):1414-25
24995905
Drug Alcohol Depend. 1996 Sep;42(1):27-37
8889401
Cochrane Database Syst Rev. 2015 Apr 17;(4):CD006754
25882271
Drug Alcohol Depend. 2007 Feb 23;87(1):20-9
16930863
J Clin Psychopharmacol. 2009 Dec;29(6):618-9
19910738
Drug Alcohol Depend. 2016 Mar 1;160:49-56
26777774
Psychopharmacology (Berl). 2000 Jan;148(1):90-8
10663422
Drug Alcohol Depend. 2015 Oct 1;155:105-10
26320827
Health Res Policy Syst. 2006 Dec 08;4:25
17156457
Addiction. 2007 Dec;102(12):1871-87
18031423
Drug Alcohol Depend. 2006 Feb 1;81(2):137-48
16102908
J Pharmacol Exp Ther. 2006 Nov;319(2):561-9
16885432
Exp Clin Psychopharmacol. 2007 Apr;15(2):123-33
17469936
Am J Drug Alcohol Abuse. 1995 Nov;21(4):469-81
8561098
J Clin Psychopharmacol. 2013 Feb;33(1):104-8
23277248
Drug Metab Dispos. 1997 Jun;25(6):657-62
9193866
Am J Psychiatry. 2007 Apr;164(4 Suppl):5-123
17569411
Br J Clin Pharmacol. 2002 Feb;53(2):214
11851650
Psychopharmacology (Berl). 2001 Sep;157(3):243-53
11605079
Drugs. 2004;64(14):1547-73
15233592
Drug Alcohol Depend. 2009 Sep 1;104(1-2):133-9
19560290
Front Psychiatry. 2012 Aug 30;3:77
22969732
Cereb Cortex. 2014 Mar;24(3):643-53
23162047
Am J Drug Alcohol Abuse. 2009;35(1):48-53
19152207
BMJ. 2008 Apr 26;336(7650):924-6
18436948
Am J Drug Alcohol Abuse. 2009;35(5):339-49
20180662
Am J Addict. 2013 Jul-Aug;22(4):352-7
23795874
Am J Addict. 2008 Jul-Aug;17(4):287-92
18612883
J Pharmacol Exp Ther. 2009 May;329(2):738-46
19197004
J Clin Psychopharmacol. 2001 Oct;21(5):522-6
11593078
Drug Alcohol Depend. 2004 May 10;74(2):115-22
15099655
Drug Alcohol Depend. 2005 Nov 1;80(2):209-21
15913920
J Psychopharmacol. 2015 Jun;29(6):678-87
25922424
Drug Alcohol Depend. 2009 Apr 1;101(1-2):34-41
19058926
Science. 1988 Nov 4;242(4879):715-23
2903550
Cochrane Database Syst Rev. 2002;(4):CD002209
12519570
Am J Drug Alcohol Abuse. 2008;34(3):293-305
18428072
Drug Alcohol Depend. 2008 Apr 1;94(1-3):142-50
18164144
NIDA Res Monogr. 1990;105:512-3
1876104
Addiction. 2003 Jan;98(1):7-22
12492751
Arch Gen Psychiatry. 2006 Feb;63(2):219-28
16461866
Am J Addict. 2007 Mar-Apr;16(2):71-8
17453607
J Clin Psychiatry. 1998 Jun;59(6):300-5
9671342
Lancet. 1989 Feb 4;1(8632):283
2563451
J Clin Psychopharmacol. 1997 Dec;17(6):485-8
9408812
Drug Alcohol Depend. 2012 Apr 1;122(1-2):11-9
22209385
J Subst Abuse Treat. 1998 May-Jun;15(3):261-5
9633038
J Clin Psychiatry. 2014 Apr;75(4):336-43
24345356
Drug Alcohol Depend. 2006 Dec 1;85(3):191-7
16730924
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD002950
22161371
Biol Psychiatry. 1992 Jun 1;31(11):1179-81
1525287
Am J Drug Alcohol Abuse. 2006;32(4):629-35
17127551
Am J Psychiatry. 1990 Jun;147(6):719-24
2343913
J Pharmacol Exp Ther. 1991 Nov;259(2):841-7
1658311
Drug Alcohol Depend. 1995 Dec;40(2):125-31
8745134
Neuropsychopharmacology. 2004 May;29(5):969-81
15039761
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Exp Clin Psychopharmacol. 2002 Aug;10(3):286-94
12233989
Addiction. 2003 Aug;98(8):1137-41
12873248
Drug Alcohol Rev. 2010 May;29(3):235-42
20565514
CNS Drug Rev. 2006 Fall-Winter;12(3-4):178-207
17227286
Nature. 1997 Apr 24;386(6627):827-30
9126740
Am J Addict. 2010 Sep-Oct;19(5):401-8
20716302
Arch Gen Psychiatry. 1991 Jan;48(1):87
1898631
Cochrane Database Syst Rev. 2003;(2):CD002209
12804430
Eur J Pharmacol. 2007 Jul 30;568(1-3):112-23
17477916
J Pharmacol Exp Ther. 2006 Apr;317(1):387-94
16352699
Arch Gen Psychiatry. 2004 Mar;61(3):264-72
14993114
JAMA Psychiatry. 2015 Jun;72(6):593-602
25887096
Addict Behav. 2014 Jun;39(6):1057-61
24642345
Br J Clin Pharmacol. 2014 Feb;77(2):337-56
23216449
Am J Psychiatry. 2010 Mar;167(3):331-40
20080983
Clin Pharmacokinet. 1997 Aug;33(2):91-102
9260033
Am J Addict. 2005 Jan-Feb;14(1):8-17
15804873
Clin Neuropharmacol. 2000 May-Jun;23(3):149-56
10895398
Drug Alcohol Depend. 2010 Jan 15;106(2-3):233-6
19783386
J Consult Clin Psychol. 2016 Mar;84(3):230-7
26460569
Clin Neuropharmacol. 1996 Feb;19(1):52-8
8867517
J Pharmacol Exp Ther. 1987 Jun;241(3):817-25
2885408
BMJ. 2004 Jun 19;328(7454):1490
15205295
Nicotine Tob Res. 2016 May;18(5):1196-201
26048168
Addict Behav. 2004 Sep;29(7):1439-64
15345275
Neuropsychopharmacology. 2005 Jan;30(1):205-11
15525998
Cochrane Database Syst Rev. 2015 May 27;(5):CD003352
26014366
J Psychopharmacol. 2015 Jan;29(1):15-23
25142405
Neuropsychopharmacology. 2011 Jan;36(1):366-7
21116260
J Subst Abuse Treat. 1997 Jul-Aug;14(4):401-4
9368218
Drug Alcohol Depend. 2013 Jul 1;131(1-2):66-70
23306096
N Engl J Med. 2002 Sep 19;347(12):951
12239274
J Subst Abuse Treat. 2013 May-Jun;44(5):541-7
23305820
Neuropharmacology. 2013 Jan;64:472-8
22796108
Mol Psychiatry. 2004 Jun;9(6):557-69
15098002
Int J Neuropsychopharmacol. 2008 May;11(3):425-38
17927843
Biol Psychiatry. 2003 Oct 15;54(8):800-5
14550679
Drug Alcohol Depend. 2014 Mar 1;136:100-7
24424425
Drug Alcohol Depend. 2015 Aug 1;153:94-103
26116930
Biol Psychiatry. 2012 Dec 1;72(11):950-6
22795453
Curr Psychiatry Rep. 2008 Oct;10(5):385-91
18803911
Am J Drug Alcohol Abuse. 2012 Mar;38(2):181-6
22221171
J Subst Abuse Treat. 2008 Jan;34(1):80-9
17574796
Drug Alcohol Depend. 1995 Oct;39(3):245-52
8556974
JAMA. 2009 Mar 18;301(11):1148-54
19293415
J Psychopharmacol. 2010 Feb;24(2):257-66
18801822
Nature. 1997 Apr 24;386(6627):830-3
9126741
Psychopharmacology (Berl). 2006 Jan;183(4):413-21
16292593
Drug Alcohol Depend. 2004 Sep 6;75(3):233-40
15283944
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007380
20166094
J Clin Psychopharmacol. 2010 Apr;30(2):152-9
20520288
J Subst Abuse Treat. 2012 Oct;43(3):303-12
22377391
Neuropsychopharmacology. 1996 Mar;14(3):159-68
8866699
J Addict Dis. 2008;27(1):13-23
18551884
J Clin Epidemiol. 2011 Apr;64(4):383-94
21195583
Behav Pharmacol. 2005 Feb;16(1):59-62
15706139
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761